Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.47 |
| ▸ | ACP1 | P24666 | 7/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11996412 | 1.00 | PTGES (0.47) | PTGESPTPN1ACP1PTPN2AKR1B1 | |
| SCHEMBL11996411 | 1.00 | PTGES (0.47) | PTGESPTPN1ACP1PTPN2AKR1B1 | |
| SCHEMBL11996392 | 0.93 | PTPN1 (0.46) | PTGESPTPN1ACP1PTPN2AKR1B1 | |
| SCHEMBL11996391 | 0.93 | PTPN1 (0.46) | PTGESPTPN1ACP1PTPN2AKR1B1 | |
| SCHEMBL3955366 | 0.93 | PTPN1 (0.46) | PTGESPTPN1ACP1PTPN2AKR1B1 | |
| SCHEMBL11996416 | 0.92 | PTGES (0.43) | PTGESPTPN1ACP1PTPN2AKR1B1 | |
| SCHEMBL11996414 | 0.92 | PTGES (0.43) | PTGESPTPN1ACP1PTPN2AKR1B1 | |
| SCHEMBL11996415 | 0.92 | PTGES (0.43) | PTGESPTPN1ACP1PTPN2AKR1B1 | |
| SCHEMBL3893584 | 0.88 | PTGES (0.47) | PTGESPTPN1ACP1PTPN2AKR1B1 | |
| SCHEMBL3893586 | 0.88 | PTGES (0.47) | PTGESPTPN1ACP1PTPN2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105001226-B | Tricyclic heterocyclic compounds and JAK inhibitor | 日产化学工业株式会社 | 2017-09-08 | — | — | CN | disclosed |
| US-9556187-B2 | Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-01-31 | — | — | US | disclosed |
| CN-103732597-B | Tricyclic heterocyclic compounds and JAK inhibitors | 日产化学工业株式会社 | 2016-08-17 | — | — | CN | disclosed |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-9216999-B2 | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| CN-105001226-A | Tricycle heterocyclic compounds and JAK inhibitors | NISSAN CHEMICAL IND LTD | 2015-10-28 | — | — | CN | disclosed |
| CN-103732597-A | Tricyclic heterocyclic compounds and JAK inhibitors | NISSAN CHEMICAL IND LTD | 2014-04-16 | — | — | CN | disclosed |
| US-8252940-B2 | 5-substituted-2-imino-thiazolidinone compounds and their use as inhibitors of bacterial infection | UNIVERSITY OF WASHINGTON (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252790-B2 | Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity | RAQUALIA PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| WO-2009137133-A2 | 5-SUBSTITUTED-2-IMINO-THIAZOLIDINONE COMPOUNDS AND THEIR USE AS INHIBITORS OF BACTERIAL INFECTION | UNIVERSITY OF WASHINGTON (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | JAK2, JAK1, JAK3 | PTGES 1550/4885PTPN1 488/4885ACP1 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.